Company Overview and News

 
RJD Green Form XML

2016-01-26 sec.gov
v3.3.1.900 Document and Entity Information - USD ($) 3 Months Ended Nov. 30, 2014 Feb. 28, 2014 Document and Entity Information:     Entity Registrant Name RJD Green, Inc.   Document Type 10-Q   Document Period End Date Nov. 30, 2014   Trading Symbol rjdg   Amendment Flag false   Entity Central Index Key 0001498210   Current Fiscal Year End Date --08-31   Entity Common Stock, Shares Outstanding 137,090,000   Entity Public Float   $ 380,000 Entity Filer Category Smaller Reporting Company   Entity
Upvote Downvote

 
RJD Green Form EX-101.SCH

2016-01-26 sec.gov
000190 - Disclosure - 2. Summary of Significant Accounting Policies: Inventory (Policies) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - 2. Summary of Significant Accounting Policies: Financial Instruments (Policies) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - 8. Commitments link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - 2.
Upvote Downvote

 
RJD Green Form EX-32

2016-01-26 sec.gov
906 Certification Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned officer of RJD Green, Inc. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the three months ended November 30, 2014 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the
Upvote Downvote

 
RJD Green Form EX-31

2016-01-26 sec.gov
302 Certification Exhibit 31.1 302 CERTIFICATION I, Rex Washburn, certify that:          1. I have reviewed this quarterly report on Form 10-Q of RJD Green, Inc.;          2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;          3.
Upvote Downvote

 
RJD Green Form 10-Q/A (Quarterly Report)

2016-01-26 sec.gov
RJD Green Form 10Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2014 -OR- [   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ________ to ________.
Upvote Downvote

 
MakeMyTrip Form EX-2

2016-01-26 sec.gov
Exhibit 2   Execution Version   INVESTOR RIGHTS AGREEMENT   dated as of January 7, 2016   between   MAKEMYTRIP LIMITED   and   CTRIP.COM INTERNATIONAL, LTD.     TABLE OF CONTENTS   ARTICLE 1 DEFINITIONS     Section 1.01 .  Definitions 1 Section 1.02 .  Other Definitional and Interpretative Provisions 3     ARTICLE 2 CORPORATE GOVERNANCE     Section 2.01 .  Board Representation 4 Section 2.02 .  Expenses and Indemnification 6 Section 2.
Upvote Downvote

 
MakeMyTrip Form EX-1

2016-01-26 sec.gov
Exhibit 1   EXECUTION VERSION     CONVERTIBLE NOTES PURCHASE AGREEMENT   by and between   MAKEMYTRIP LIMITED   and   CTRIP.COM INTERNATIONAL, LTD.   Dated as of January 7, 2016       Table of Contents   ARTICLE I Definitions and Interpretation   1         Section 1.1 Definitions   1         Section 1.2 Interpretation and Rules of Construction   5         ARTICLE II PURCHASE AND SALE OF THE NOTES   6         Section 2.
Upvote Downvote

 
MakeMyTrip Form EX-99.3

2016-01-26 sec.gov
EX-99.3 Exhibit 99.3 Execution Version       MAKEMYTRIP LIMITED AND THE BANK OF NEW YORK MELLON, SINGAPORE BRANCH as Trustee INDENTURE Dated as of January 14, 2016 4.25% Convertible Notes due 2021       TABLE OF CONTENTS   Article 1    DEFINITIONS    Section 1.01    Definitions      1    Article 2    ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES    Section 2.01    Designation and Amount      10    Section 2.
Upvote Downvote

 
MakeMyTrip Form EX-99.2

2016-01-26 sec.gov
EX-99.2 Exhibit 99.2       CONVERTIBLE NOTES PURCHASE AGREEMENT by and between MAKEMYTRIP LIMITED and CTRIP.COM INTERNATIONAL, LTD. Dated as of January 7, 2016       Table of Contents   ARTICLE I Definitions and Interpretation      1    Section 1.1   Definitions      1    Section 1.2   Interpretation and Rules of Construction      5    ARTICLE II PURCHASE AND SALE OF THE NOTES      6    Section 2.1   Sale and Issuance of Notes      6    Section 2.
Upvote Downvote

 
MakeMyTrip Form EX-99.1

2016-01-26 sec.gov
EX-99.1 Exhibit 99.1 INVESTOR RIGHTS AGREEMENT dated as of January 7, 2016 between MAKEMYTRIP LIMITED and CTRIP.COM INTERNATIONAL, LTD. TABLE OF CONTENTS   ARTICLE 1    DEFINITIONS   Section 1.01.    Definitions      1   Section 1.02.    Other Definitional and Interpretative Provisions      3   ARTICLE 2    CORPORATE GOVERNANCE   Section 2.01.    Board Representation      4   Section 2.02.    Expenses and Indemnification      6   Section 2.
Upvote Downvote

 
Swift Transportation Form EX-99

2016-01-26 sec.gov
Exhibit     Exhibit 99       P.O. Box 29243 - Phoenix, Arizona 85038-9243   2200 S. 75th Avenue - Phoenix, Arizona 85043   (602) 269-9700    January 25, 2016 Dear Fellow Stockholders of Swift Transportation Company (NYSE: SWFT), A summary of our key results for the three months and years ended December 31st is shown below:   Three Months Ended December 31,   Year Ended December 31,   2015   2014   2013   2015   2014   2013   Unaudited   ($ in millions, except per share data) Operating Revenue $
Upvote Downvote

 
Customers Bancorp Form EX-99.1

2016-01-26 sec.gov
Exhibit 99.1 Customers Bancorp 1015 Penn Avenue Wyomissing, PA 19610   Contacts: Jay Sidhu, Chairman & CEO 610-935-8693 Richard Ehst, President & COO 610-917-3263 Investor Contact: Robert Wahlman, CFO 610-743-8074       CUSTOMERS BANCORP ANNOUNCES PRICING OF   PUBLIC OFFERING OF PREFERRED STOCK   Wyomissing, PA – January 22, 2016 – Customers Bancorp, Inc. (the "Company") (NYSE: CUBI), the parent company for Customers Bank, today announced the pricing of its public offering of 1,000,000 shares of
Upvote Downvote

 
Customers Bancorp Form EX-1.1

2016-01-26 sec.gov
Exhibit 1.1 Customers Bancorp, Inc. Fixed-to-Floating Rate Perpetual Preferred Stock, Series D Underwriting Agreement January 22, 2016 UBS Securities LLC Morgan Stanley & Co. LLC as Representatives of the several Underwriters named in Schedule I hereto c/o UBS Securities LLC 1285 Avenue of the Americas New York, NY 10019 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: Customers Bancorp, Inc.
Upvote Downvote

 
Customers Bancorp Form 8-K (Current Report/Significant Event)

2016-01-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.   20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported):  January 22, 2016 __________________ CUSTOMERS BANCORP, INC. (Exact Name of Registrant as specified in its charter) __________________ Pennsylvania 001-35542 27-2290659 (State or other jurisdiction of incorporation) (Commission File Number) (I
Upvote Downvote

 
S&W Seed Form 424B2 (Prospectus)

2016-01-26 sec.gov
January 22, 2016 424(b)(2) DOC Filed Pursuant to Rule 424(b)(2) Registration No. 333-208605  1,923,077 Shares of Common Stock and 576,923 Shares of Common Stock Pursuant to an Oversubscription Right We are conducting a rights offering pursuant to which we are distributing to holders of our common stock, convertible notes and accompanying warrants, at no charge, non-transferable subscription rights to purchase shares of our common stock.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...